Cambrex's $120m Iowa Build-Out: Moving Liquid-Phase Peptides Into a Century-Old Plant

On 29 October Cambrex broke ground on a $120m expansion at its Charles City, Iowa site, adding 160,000 litres of capacity, lifting the site's total volume by roughly 25% to nearly one million litres, with completion slated for Q4 2028 for small-molecule APIs and synthetic peptides. Against the March feasibility-study language of 140,000 litres and a 20% gain in large-scale capacity, the project grew about 14% in eight months. The more interesting detail is the route: the announcement specifies commercial-scale liquid-phase peptide manufacturing, a deliberate mismatch with a global peptide build-out dominated by solid-phase. US-sited capacity also carries a country-of-origin credential under Section 232 tariffs.

On 29 October Cambrex held a groundbreaking ceremony at its Charles City, Iowa site, announcing on 30 October a $120m investment adding 160,000 litres of manufacturing capacity, raising the site's total volume by approximately 25% to nearly one million litres, with completion expected in Q4 2028. The capacity will serve development and commercial manufacturing of small-molecule APIs, synthetic peptides and pharmaceutical intermediates.

The guest list was notable: Iowa Lieutenant Governor Chris Cournoyer and US Senator Chuck Grassley, alongside state and local economic development officials. For a privately held CDMO, that turnout signals two things: substantive local support for the project, and a desire to be seen on US manufacturing.

There was a second layer to the date: the Charles City site turns 100. A chemical plant that started up in 1926 added a peptide line at the opening of its second century.

Eight months, 14% bigger

Read the two announcements side by side and a detail surfaces. On 23 March 2026 Cambrex said it had completed engineering studies for the new plant: 140,000 litres, a 20% increase in large-scale capacity, groundbreaking in late 2026. October's announcement says 160,000 litres and a 25% lift in total site volume.

Between feasibility study and groundbreaking, the unit grew roughly 14%. For a heavy-asset project that is not a number you change casually: building shell, utilities, reactor specifications and waste treatment all have to be re-engineered. There is really only one explanation. Demand strengthened after the study, peptides above all.

The word that matters is liquid

The March release was specific about the plant's capability envelope: complex chemistry including controlled substances, highly potent APIs, and commercial-scale liquid-phase peptide manufacturing.

Of those three, liquid-phase peptides deserve a pause. This global peptide capacity wave has been overwhelmingly solid-phase (SPPS): WuXi AppTec's solid-phase peptide reactors passed 100,000 litres at end-2025 and, per sell-side research, are expanding toward 130,000 litres; Asymchem went from 45,000 to 69,000 litres. SPPS is versatile, fast to switch and well suited to conventional 10–30 residue molecules. Its weakness is resin and solvent consumption, which makes the cost curve steep at tonne scale.

Liquid-phase synthesis (LPPS) takes the other road: fragment condensation in solution, suited to long chains and large volumes, with better unit cost and solvent intensity, but far more demanding in process development, racemisation control and purification. Once a GLP-1 asset reaches hundreds of kilograms to tonnes, liquid-phase becomes the unavoidable cost lever. Commercial-scale LPPS capacity is considerably scarcer than SPPS.

Placing that line in Iowa, alongside HPAPI and controlled-substance handling, points at a very specific customer: long-acting peptides and complex small molecules in late-stage programmes that need a US origin.

Country of origin is the second card

The Section 232 pharmaceutical tariffs that landed in late September 2026 wrote origin into the cost structure: a 100% baseline on patented drugs, APIs and key starting materials; 15% for the EU, Japan, Korea and Switzerland; 10% for the UK. Avoiding it requires either a specified share of US-based production or falling into an exempt category such as generics, biosimilars, ADCs or cell and gene therapies.

Under that framework, Charles City is not simply 160,000 extra litres. It is a US-origin credential. For customers holding federal funding, selling to government, or merely unwilling to add a tariff line to a quote, the credential may carry a premium above the price of the capacity itself.

The mid-cap grid: modality times geography

Cambrex's coordinates are clear: 2,000 people, 45 years of history, sites in North America and Europe, a drug-substance specialist that does not compete on antibody litres. It is simultaneously running a $30m Milan expansion (the site's 80th anniversary, completion in H2 2027, focused on tides, HPAPIs and controlled substances).

Leadership is moving in step: Claudio Russolo attended the groundbreaking as chief operating officer and incoming chief executive. A CEO transition that does not change strategy usually means the board has endorsed the specialisation-plus-dual-geography strategy.

By comparison, Samsung Biologics is buying scale (60,000 litres at Rockville, 87.92% of PolyPeptide, a rights offering of about KRW 2.665tn), Lonza is filling network gaps in bioconjugation (three 1,200-litre multiproduct suites at Visp, online 2028), and WuXi AppTec is running a China-Singapore-Delaware triangle. Cambrex has picked a fourth path: stop competing on litres, occupy the modality-times-geography grid.

Editor's note: three things to track

First, what stage of programme the liquid-phase line picks up when it starts in Q4 2028. Liquid-phase economics only show at tonne scale; if early-phase work dominates, the depreciation line will look ugly.

Second, whether dosage-form capability follows. Cambrex has long been a drug-substance house, yet peptide pain points often sit downstream in formulation (long-acting release, prefilled devices, lyophilisation). Substance-only positioning gets stuck on end-to-end awards.

Third, whether Milan plus Iowa becomes a quoting template. If customers start asking for one asset qualified in both Europe and the US, dual geography shifts from a differentiator to a licence to bid.

For investors, the weight of this news is not the $120m. It is the direction it reveals: the peptide capacity race is moving from who has more reactors to who can bend the cost curve at tonne scale with a selectable origin. The first is a capital contest; the second is a contest of process know-how and geography.